Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Stem cell therapy | 1 |
Target- |
Mechanism Stem cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FFAR3 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GPR40 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date15 Apr 2025 |
Sponsor / Collaborator [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Allogenic adipose-derived regenerative cells(University of Southern Denmark) | Perianal fistula More | Phase 2 Clinical |
TUG-891 ( GPR120 ) | Diabetes Mellitus, Type 2 More | Preclinical |
CVH-174 | Gram-Positive Bacterial Infections More | Preclinical |
Bacterial proteins inhibitors(University of Southern Denmark) ( Bacterial proteins ) | Staphylococcus Aureus Infections More | Preclinical |
TUG-424 ( GPR40 ) | Diabetes Mellitus, Type 2 More | Preclinical |